Medicare And Alzheimer's Drugs: Grassroots Campaign Opposing Coverage Aims To ‘Take On Big Pharma’

Nearly 5,000 comments from individuals on CMS’ proposal to restrict coverage of Alzheimer’s drugs argue that Aduhelm should never have been approved and should not be covered. The outpouring is surprising in light of expectations there would be a flood of patient comments urging broader coverage.